Wockhardt Ltd Zaynich progress

Wockhardt received U.S. FDA approval for ZAYNICH (cefepime and zidebactam), a novel antibiotic aimed at multidrug-resistant infections, after a long development effort. Market coverage says the drug has been viewed as a potential turnaround product for the company, with analysts and investors focusing on its launch path in the U.S. and India.